|
|
| Line 3: |
Line 3: |
| | <StructureSection load='6phc' size='340' side='right'caption='[[6phc]], [[Resolution|resolution]] 2.90Å' scene=''> | | <StructureSection load='6phc' size='340' side='right'caption='[[6phc]], [[Resolution|resolution]] 2.90Å' scene=''> |
| | == Structural highlights == | | == Structural highlights == |
| - | <table><tr><td colspan='2'>[[6phc]] is a 6 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human] and [http://en.wikipedia.org/wiki/Plafa Plafa]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6PHC OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6PHC FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[6phc]] is a 6 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] and [https://en.wikipedia.org/wiki/Plasmodium_falciparum Plasmodium falciparum]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6PHC OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6PHC FirstGlance]. <br> |
| - | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene></td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.9Å</td></tr> |
| - | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[6phb|6phb]]</td></tr> | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene></td></tr> |
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6phc FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6phc OCA], [http://pdbe.org/6phc PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6phc RCSB], [http://www.ebi.ac.uk/pdbsum/6phc PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6phc ProSAT]</span></td></tr> | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6phc FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6phc OCA], [https://pdbe.org/6phc PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6phc RCSB], [https://www.ebi.ac.uk/pdbsum/6phc PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6phc ProSAT]</span></td></tr> |
| | </table> | | </table> |
| - | <div style="background-color:#fffaf0;">
| + | == Function == |
| - | == Publication Abstract from PubMed == | + | [https://www.uniprot.org/uniprot/OS25_PLAFO OS25_PLAFO] |
| - | Transmission-blocking vaccines have the potential to be key contributors to malaria elimination. Such vaccines elicit antibodies that inhibit parasites during their development in Anopheles mosquitoes, thus breaking the cycle of transmission. To date, characterization of humoral responses to Plasmodium falciparum transmission-blocking vaccine candidate Pfs25 has largely been conducted in pre-clinical models. Here, we present molecular analyses of human antibody responses generated in a clinical trial evaluating Pfs25 vaccination. From a collection of monoclonal antibodies with transmission-blocking activity, we identify the most potent transmission-blocking antibody yet described against Pfs25; 2544. The interactions of 2544 and three other antibodies with Pfs25 are analyzed by crystallography to understand structural requirements for elicitation of human transmission-blocking responses. Our analyses provide insights into Pfs25 immunogenicity and epitope potency, and detail an affinity maturation pathway for a potent transmission-blocking antibody in humans. Our findings can be employed to guide the design of improved malaria transmission-blocking vaccines.
| + | |
| | | | |
| - | Potent antibody lineage against malaria transmission elicited by human vaccination with Pfs25.,McLeod B, Miura K, Scally SW, Bosch A, Nguyen N, Shin H, Kim D, Volkmuth W, Ramisch S, Chichester JA, Streatfield S, Woods C, Schief WR, Emerling D, King CR, Julien JP Nat Commun. 2019 Sep 24;10(1):4328. doi: 10.1038/s41467-019-11980-6. PMID:31551421<ref>PMID:31551421</ref>
| + | ==See Also== |
| - | | + | *[[Antibody 3D structures|Antibody 3D structures]] |
| - | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
| + | *[[3D structures of human antibody|3D structures of human antibody]] |
| - | </div>
| + | |
| - | <div class="pdbe-citations 6phc" style="background-color:#fffaf0;"></div>
| + | |
| - | == References ==
| + | |
| - | <references/>
| + | |
| | __TOC__ | | __TOC__ |
| | </StructureSection> | | </StructureSection> |
| - | [[Category: Human]] | + | [[Category: Homo sapiens]] |
| | [[Category: Large Structures]] | | [[Category: Large Structures]] |
| - | [[Category: Plafa]] | + | [[Category: Plasmodium falciparum]] |
| - | [[Category: Julien, J P]] | + | [[Category: Julien JP]] |
| - | [[Category: McLeod, B R]] | + | [[Category: McLeod BR]] |
| - | [[Category: Antigen]]
| + | |
| - | [[Category: Complex]]
| + | |
| - | [[Category: Fab]]
| + | |
| - | [[Category: Immune system]]
| + | |
| - | [[Category: Immunoglobulin]]
| + | |
